Bangladesh Medical Research Council (BMRC)
Since the first cardiac valve replacement in the early sixth decade of the last century, the search continued for ideal cardiac valve substitute with proven structural durability over a period of 10 to 20 years, central flow orifice without transvalvular gradient, absence of host reactivity deleterious to valve function, non-thrombogenecity without the use of anti-coagulant, resistance to infective endo carditis, availability with cost effectiveness and ease of surgical implantation1 . The experience with prosthetic tissue valves commenced almost
simultaneously with the silastic ball valve and the aortic homograft valve. Homograft aortic valves have been used either as fresh, antibiotic sterilized or cryo-preserved, as a replacement for mitral valve, aortic valve, aortic root replacement, or a conduit between the right ventricle and the pulmonary trunk.